Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule

Clinical TrialsTherapueticsFDA

Aug 25

Written By Corey Hubbard

Audio Block

Double-click here to upload or link to a .mp3. Learn more

GlassBury Cares Podcast

Episode #31

Lung CancerResearchDr. Mariam DunduaLantern Pharma

Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn

Brain Breakthrough: Oragenics and Southern Star Pioneer New Hope for Concussion Treatment